“Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies”, J of Skin, vol. 5, no. 6, p. s66, Nov. 2021, doi: 10.25251/skin.5.supp.66.